SCHEMBL812971

SCHEMBL812971

NC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 15/20 0.76
MAPT P10636 2/20 0.60
KMT2A Q03164 1/20 0.60
KCNE1 P15382 1/20 0.56
KCNQ1 P51787 1/20 0.56
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.46
PARP1 P09874 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18782553 0.87 KCNN4 (0.72) KCNN4MAPTKMT2AKCNE1KCNQ1
Senicapoc SCHEMBL1443805 0.87 KCNN4 (1.00) KCNN4MAPTKMT2AKCNE1KCNQ1
SCHEMBL2337394 0.87 KCNN4 (1.00) KCNN4MAPTKMT2AKCNE1KCNQ1
SCHEMBL6167052 0.82 KCNN4 (0.61) KCNN4MAPTKMT2AKCNE1KCNQ1
SCHEMBL17592012 0.82 KCNN4 (0.56) KCNN4MAPTKMT2AKCNE1KCNQ1
SCHEMBL13950934 0.82 KCNN4 (1.00) KCNN4MAPTKMT2AKCNE1KCNQ1
SCHEMBL28316877 0.81 KCNN4 (0.59) KCNN4KMT2AKCNE1KCNQ1TSHR
SCHEMBL14437486 0.81 KCNN4 (0.65) KCNN4MAPTKMT2AKCNE1KCNQ1
SCHEMBL14437487 0.81 KCNN4 (1.00) KCNN4MAPTKMT2AKCNE1KCNQ1
SCHEMBL12811863 0.81 KCNN4 (0.86) KCNN4KCNE1KCNQ1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119246718-A Chiral analysis method of semaglutin series intermediates 杭州澳赛诺医药技术有限公司 2025-01-03 CN claimed
CN-115943138-A Compositions comprising GARDOS channel antagonists and uses thereof 阿迪玛生物有限责任公司 2023-04-07 CN claimed
US-20110124735-A1 CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS NEURO SEARCH A/S (DK) 2011-05-26 US claimed
EP-2192896-A1 CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS NEUROSEARCH A/S (DK) 2010-06-09 EP claimed
WO-2009027292-A1 CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS NEUROSEARCH A/S (DK) 2009-03-05 WO claimed
WO-2003004010-A1 CARBONYLAMINO DERIVATIVES USEFUL FOR OBTAINING IMMUNE REGULATION POSEIDON PHARMACEUTICALS A/S (DK) 2003-01-16 WO claimed
EP-0316820-B1 THIAZOLE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-01-22 EP claimed
US-4921887-A ANTIALLERGENS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-01 US claimed
CN-119246718-A Chiral analysis method of semaglutin series intermediates 杭州澳赛诺医药技术有限公司 2025-01-03 CN disclosed
US-20230248672-A1 COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES ADIMABIO LLC (US) 2023-08-10 US disclosed
US-20230248672-A1 COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES ADIMABIO LLC (US) 2023-08-10 US disclosed
US-20230248672-A1 COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES ADIMABIO LLC (US) 2023-08-10 US disclosed
EP-4181908-A2 COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES Adimabio LLC (US) 2023-05-24 EP disclosed
EP-4181908-A2 COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES Adimabio LLC (US) 2023-05-24 EP disclosed
EP-1158971-A1 GARDOS CHANNEL ANTAGONISTS Icagen, Inc. (US) 2001-12-05 EP disclosed
US-6288122-B1 A TRIPHENYL ACETAMIDE ICAGEN, INC. 2001-09-11 US disclosed
WO-2000050026-A1 GARDOS CHANNEL ANTAGONISTS ICAGEN, INC. (US) 2000-08-31 WO disclosed
EP-0316820-B1 THIAZOLE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-01-22 EP disclosed
EP-0444068-A1 TRIALKYSILYL ESTERS OF AMINO ACIDS AND THEIR USE IN THE SYNTHESIS OF PEPTIDES PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) 1991-09-04 EP disclosed
WO-1990005738-A1 TRIALKYSILYL ESTERS OF AMINO ACIDS AND THEIR USE IN THE SYNTHESIS OF PEPTIDES PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) 1990-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248672-A1 COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES CACNA1G, CACNA1I, CACNG2 KCNN4 36/4885MAPT 4593/4885KMT2A 1832/4885
US-20110124735-A1 CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS NFKBIA, TNF, LTC4S KCNN4 4646/4885MAPT 1906/4885KMT2A 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.